Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Right now MK-1775 is in phase I/II clinical trials for various cancers
but the molecular target was not previously reported
Petherick KJ
and may inspire novel drug discovery efforts aimed at the development of drugs targeting oncogenic RAS
(R)-2-HG - a-KG-dependent dioxygenases inhibitor. CAS# 103404-90-6 60225 Right now MK-1775 is inMutations, CAS No. 103404 90 6, in IDH1 and IDH2, the genes coding for isocitrate dehydrogenases 1 and 2, are common in several human cancers, such as leukemia and glioma, and result in overproduction of the (R) enantiomer of 2 hydroxyglutarate [(R) 2 HG]. Elucidation of the role of IDH mutations and (R) 2 HG in leukemogenesis has been hampered by a lack of appropriate cell based models. It has been recently reported that a canonical IDH1 mutant, IDH1